Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

NCT05282797 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Cannabinoid Intoxication

Interventions

DRUG: ANEB-001
DRUG: Placebo

Sponsor

Anebulo Pharmaceuticals